Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer

Journal of Biomedicine and Biotechnology

Volumn 2009, Issue , 2009, Pages

  Milecki, Piotr ^a   Baczyk, MacIej ^b   Skowronek, Janusz ^a   Antczak, Andrzej ^b   Kwias, Zbigniew ^b   Martenka, Piotr ^a  

^a GREATER POLAND CANCER CENTRE   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; FLUTAMIDE; GOSERELIN;

ADJUVANT THERAPY; ADULT; ADVERSE OUTCOME; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; WHOLE PELVIC RADIOTHERAPY; ADENOCARCINOMA; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEOPLASM; POLAND; PROSPECTIVE STUDY; PROSTATE TUMOR; RISK FACTOR;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; FLUTAMIDE; GOSERELIN; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; POLAND; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RISK FACTORS;

EID: 71149087272     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2009/625394     Document Type: Article

References (38)

1. Bray F., Sankila R., Ferlay J., Parkin D. M, Estimates of cancer incidence and mortality in Europe in 1995 European Journal of Cancer 2002 38 1 99 166 (Pubitemid 34031832)
2. Black R. J., Bray F., Ferlay J., Parkin D. M., Cancer incidence and mortality in the European union: cancer registry data and estimates of national incidence for 1990 European Journal of Cancer Part A 1997 33 7 1075 1107
3. Greenlee R. T., Hill-Harmon M. B., Murray T., Thun M., Cancer statistics, 2001 CA: A Cancer Journal for Clinicians 2001 51 1 15 36
4. Grossfeld G. D., Chang J. J., Broering J. M., Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database Journal of Urology 2000 163 4 1171 1177
5. Zietman A. L., Dose escalation in localized prostate cancer: make no assumptions International Journal of Radiation Oncology Biology Physics 2002 54 3 635 636
6. Hanks G. E., Pajak T. F., Porter A., Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 9202 Journal of Clinical Oncology 2003 21 21 3972 3978
7. Laverdire J., Gomez J. L., Cusan L., Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer International Journal of Radiation Oncology Biology Physics 1997 37 2 247 252
8. Roach M. III, Lu J., Pilepich M. V., Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials International Journal of Radiation Oncology Biology Physics 2000 47 3 617 627
9. Pilepich M. V., Winter K., Lawton C. A., Androgen suppression adjuvant to definitive radiotherapy in prostate carcinomalong-term results of phase III RTOG 85-31 International Journal of Radiation Oncology Biology Physics 2005 61 5 1285 1290 (Pubitemid 40470408)
10. Roach M. III, DeSilvio M., Lawton C., Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 Journal of Clinical Oncology 2003 21 10 1904 1911 (Pubitemid 46606377)
11. Roach M. III, DeSilvio M., Valicenti R., Whole-pelvis, mini-pelvis, or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial International Journal of Radiation Oncology Biology Physics 2006 66 3 647 653
12. Vargas C. E., Galalae R., Demanes J., Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation International Journal of Radiation Oncology Biology Physics 2005 63 5 1474 1482
13. Zapatero A., Garcia-Vicente F., Modolell I., Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect International Journal of Radiation Oncology Biology Physics 2004 59 5 1343 1351
14. Ploysongsang S. S., Aron B. S., Shehata W. M., Radiation therapy in prostate cancer: whole pelvis with prostate boost or small field to prostate? Urology 1992 40 1 18 26
15. Lawton C. A., DeSilvio M., Roach M. III, An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions International Journal of Radiation Oncology Biology Physics 2007 69 3 646 655
16. Seaward S. A., Weinberg V., Lewis P., Leigh B., Phillips T. L., Roach M. III, Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer International Journal of Radiation Oncology Biology Physics 1998 42 5 1055 1062
17. Seaward S. A., Weinberg V., Lewis P., Leigh B., Phillips T. L., Roach M. III, Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation Cancer Journal from Scientific American 1998 4 6 370 377
18. Roach M. III, Marquez C., Yuo H.-S., Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason Score in men with clinically localized prostate cancer International Journal of Radiation Oncology Biology Physics 1994 28 1 33 37
19. Roach M. III, Hanks G., Thames H. Jr., Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference International Journal of Radiation Oncology Biology Physics 2006 65 4 965 974
20. Milecki P., Piotrowski T., Dymnicka M., The comparison of radiotherapy techniques for treatment of the prostate cancer: the three-field vs. the four-field Neoplasma 2004 51 1 64 69
21. Cox J. D., Stetz J., Pajak T. F., Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) International Journal of Radiation Oncology Biology Physics 1995 31 5 1341 1346
22. American Society for Therapeutic Radiology, Oncology Consensus Panel, Consensus statement: guidelines for PSA following radiation therapy International Journal of Radiation Oncology Biology Physics 1997 37 5 1035 1041
23. Dirix P., Haustermans K., Junius S., Withers R., Oyen R., Van Poppel H., The role of whole pelvic radiotherapy in locally advanced prostate cancer Radiotherapy and Oncology 2006 79 1 1 14
24. American Urology Association Guidelines for Prostate Cancer,. http://www.auanet.org
25. European Urology Association Guidelines for Prostate Cancer,. http://www.uroweb.org
26. National Cancer Comprehensive Network.Prostate Cancer,. v.2, 2008, http://www.nccn.org
27. Bolla M., Gonzalez D., Warde P., Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin The New England Journal of Medicine 1997 337 5 295 300
28. Pilepich M. V., Winter K., Lawton C. A., Androgen suppression adjuvant to definitive radiotherapy in prostate carcinomalong-term results of phase III RTOG 85-31 International Journal of Radiation Oncology Biology Physics 2005 61 5 1285 1290 (Pubitemid 40470408)
29. Milecki P., Kwias Z., Martenka D. J., Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis Neoplasma 2007 54 1 7 15
30. Wang D., Lawton C., Pelvic lymph node irradiation for prostate cancer: who, why, and when? Seminars in Radiation Oncology 2008 18 1 35 40
31. Pilepich M. V., Winter K., John M. J., Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate International Journal of Radiation Oncology Biology Physics 2001 50 5 1243 1252
32. Friedman J., Dunn R. L., Wood D., Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer Journal of Urology 2008 179 3 911 916
33. DAmico A. V., Manola J., Loffredo M., Renshaw A. A., DellaCroce A., Kantoff P. W., 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial Journal of the American Medical Association 2004 292 7 821 827
34. Crook J., Ludgate C., Malone S., Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer International Journal of Radiation Oncology Biology Physics 2004 60 1 15 23
35. Bolla M., Collette L., Blank L., Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial The Lancet 2002 360 9327 103 108
36. Denham J. W., Steigler A., Lamb D. S., Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial Lancet Oncology 2005 6 11 841 850
37. Roach M. III, Bae K., Speight J., Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 Journal of Clinical Oncology 2008 26 4 585 591
38. Zelefsky M. J., Leibel S. A., Burman C. M., Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy International Journal of Radiation Oncology Biology Physics 1994 29 4 755 761